Alzheimer's disease and iatrogenicity of antipsychotics
Objectives
Reduce the inappropriate use of antipsychotic drugs in the Alzheimer’s disease
Methods & tools
- AMI Clinical Practice Indicator No. 1: Antipsychotics in the person living with Alzheimer's disease, March 2013
- Programme AMI Alzheimer - brochure, April 2012
- Reducing the use of antipsychotic drugs in the Alzheimer’s disease - press conference, November 2009
- Behavioral disorders - brochure, 2009
- Alzheimer’s disease and related conditions: Disclosing the diagnosis and providing support – quick reference guide, September 2009
- Alzheimer’s disease and related conditions: Management of behavioural disorders - quick reference guide, May 2009
- Alzheimer’s disease and related conditions: Health monitoring for family carers - quick reference guide, February 2010
INTERVENTION
(1) | (2) during | (3) after | ||
 | ||||
| NL prescription | ||||
| Avoiding the risk | Identifying the risk | Decreasing the risk | ||
New guidelines on behaviour disorders and confusion in people with AD that describe proper use of NL and other psychotropic drugs as well as new non pharmaceutical techniques of care [behavioural disorders] | Local Alert Indicator
| Local Mastering indicator based
on the review of prescriptions for identified people with AD exposed to
NL, in order to correct inappropriate prescriptions. | ||
AIM: to decrease the neuroleptic prescription, improve management of BPSD
and improve quality of life
Results (clinical impact)
- ISQua: Limit the overuse of Neuroleptics in Alzheimer’s disease: a global issue (brochure) - Paris, October 12, 2010
- Symposium HAS - BMJ : Clinical impact of quality improvement - Nice, April 19, 2010
- Abstract 282 : Reducing the iatrogenicity of neuroleptics in patients with Alzheimer’s disease
03/26/2013
For more information
May 21, 2013 - 5:39 PM - URL: http://www.has-sante.fr/portail/jcms/c_1055540/en/alzheimer-s-disease-and-iatrogenicity-of-antipsychotics?userLang=en
Français